Andrea Bertotti
Andrea Bertotti
University of Torino - School of Medicine
Email verificata su ircc.it
Titolo
Citata da
Citata da
Anno
MET signalling: principles and functions in development, organ regeneration and cancer
L Trusolino, A Bertotti, PM Comoglio
Nature reviews Molecular cell biology 11 (12), 834-848, 2010
10582010
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ...
Cancer discovery 1 (6), 508-523, 2011
7362011
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
5362016
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
5282013
A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth
L Trusolino, A Bertotti, PM Comoglio
Cell 107 (5), 643-654, 2001
5232001
Stromal contribution to the colorectal cancer transcriptome
C Isella, A Terrasi, SE Bellomo, C Petti, G Galatola, A Muratore, A Mellano, ...
Nature genetics 47 (4), 312-319, 2015
4442015
Interrogating open issues in cancer precision medicine with patient-derived xenografts
AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ...
Nature Reviews Cancer 17 (4), 254, 2017
3712017
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ...
Nature 568 (7753), 511-516, 2019
3432019
The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ...
Nature 526 (7572), 263-267, 2015
3262015
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ...
Cell reports 7 (1), 86-93, 2014
2522014
HER2 activating mutations are targets for colorectal cancer treatment
SM Kavuri, N Jain, F Galimi, F Cottino, SM Leto, G Migliardi, ...
Cancer discovery 5 (8), 832-841, 2015
1942015
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
G Migliardi, F Sassi, D Torti, F Galimi, ER Zanella, M Buscarino, D Ribero, ...
Clinical Cancer Research 18 (9), 2515-2525, 2012
1742012
β4 integrin activates a Shp2–Src signaling pathway that sustains HGF-induced anchorage-independent growth
A Bertotti, PM Comoglio, L Trusolino
The Journal of cell biology 175 (6), 993-1003, 2006
1532006
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity
L Trusolino, S Cavassa, P Angelini, M Andò, A Bertotti, PM Comoglio, ...
The FASEB Journal 14 (11), 1629-1640, 2000
1522000
Sema3E–Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice
A Casazza, V Finisguerra, L Capparuccia, A Camperi, JM Swiercz, ...
The Journal of clinical investigation 120 (8), 2684, 2010
1492010
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer
C Isella, F Brundu, SE Bellomo, F Galimi, E Zanella, R Porporato, C Petti, ...
Nature communications 8 (1), 1-16, 2017
1262017
Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations
F Galimi, D Torti, F Sassi, C Isella, D Corà, S Gastaldi, D Ribero, ...
Clinical cancer research 17 (10), 3146-3156, 2011
1232011
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors
P Luraghi, G Reato, E Cipriano, F Sassi, F Orzan, V Bigatto, F De Bacco, ...
Cancer research 74 (6), 1857-1869, 2014
1122014
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
S Corso, E Ghiso, V Cepero, JR Sierra, C Migliore, A Bertotti, L Trusolino, ...
Molecular cancer 9 (1), 1-13, 2010
1112010
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer …
A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ...
CD-11-0109.[Abstract][CrossRef][Google Scholar], 0
108
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20